Extracellular gadolinium-based contrast media: Differences in diagnostic efficacy

European Journal of Radiology

Volumn 66, Issue 2, 2008, Pages 168-174

  van der Molen, Aart J ^a   Bellin, Marie France ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Contrast media; Efficacy studies; Gadolinium; Magnetic resonance imaging

Indexed keywords

BINDING SITES; DIAGNOSTIC RADIOGRAPHY; MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PROTEINS;

DELINEATION; UNENHANCED SEQUENCES;

GADOLINIUM;

CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIC ACID; GADOTERIDOL; GADOVERSETAMIDE;

ARTERY OCCLUSION; ARTICLE; BRAIN METASTASIS; BRAIN PERFUSION; CENTRAL NERVOUS SYSTEM TUMOR; CHILD CARE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; HUMAN; IMAGE QUALITY; LOW DRUG DOSE; MAGNETIC RESONANCE ANGIOGRAPHY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OSMOLALITY; PRIORITY JOURNAL; PROTEIN BINDING; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO; SINGLE DRUG DOSE; TREATMENT INDICATION; TUMOR DIAGNOSIS; VISCOSITY;

CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; GADOLINIUM; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING;

EID: 43049112722     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2008.02.010     Document Type: Article

References (94)

1. De Haën C. Conception of the first magnetic resonance imaging contrast agents: a brief history. Top Magn Reson Imaging 12 (2001) 221-230
2. Haynes B. Can it work? Does it work? Is it worth it? The testing of healthcare interventions is evolving. BMJ 319 (1999) 652-653
3. Stack J.P., Antoun N.M., Jenkins J.P., Metcalfe R., and Isherwood I. Gadolinium-DTPA as a contrast agent in magnetic resonance imaging of the brain. Neuroradiology 30 (1988) 145-154
4. Hesselink J.R., Healy M.E., Press G.A., and Brahme F.J. Benefits of Gd-DTPA for MR imaging of intracranial abnormalities. J Comput Assist Tomogr 12 (1988) 266-274
5. Russell E.J., Schaible T.F., Dillon W., et al. Multicenter double-blind placebo-controlled study of gadopentetate dimeglumine as an MR contrast agent: evaluation in patients with cerebral lesions. AJR Am J Roentgenol 152 (1989) 813-823
6. Runge V.M., Schaible T.F., Goldstein H.A., et al. Gd-DTPA. Clinical efficacy. Radiographics 8 (1988) 147-159
7. Stimac G.K., Porter B.A., Olson D.O., Gerlach R., and Genton M. Gadolinium-DTPA-enhanced MR imaging of spinal neoplasms: preliminary investigation and comparison with unenhanced spin-echo and STIR sequences. AJR Am J Roentgenol 151 (1988) 1185-1192
8. Sze G., Stimac G.K., Bartlett C., et al. Multicenter study of gadopentetate dimeglumine as an MR contrast agent: evaluation in patients with spinal tumors. AJNR Am J Neuroradiol 11 (1990) 967-974
9. Bird C.R., Drayer B.P., Medina M., Rekate H.L., Flom R.A., and Hodak J.A. Gd-DTPA-enhanced MR imaging in pediatric patients after brain tumor resection. Radiology 169 (1988) 123-126
10. Elster A.D., and Rieser G.D. Gd-DTPA-enhanced cranial MR imaging in children: initial clinical experience and recommendations for its use. AJR Am J Roentgenol 153 (1989) 1265-1268
11. Eldevik O.P., and Brunberg J.A. Gadopentetate dimeglumine-enhanced MR of the brain: clinical utility and safety in patients younger than two years of age. AJNR Am J Neuroradiol 15 (1994) 1001-1008
12. Elster A.D. Cranial MR imaging with Gd-DTPA in neonates and young infants: preliminary experience. Radiology 176 (1990) 225-230
13. Goyen M., and Debatin J.F. Gadopentetate dimeglumine-enhanced three-dimensional MR-angiography: dosing, safety, and efficacy. J Magn Reson Imaging 19 (2004) 261-273
14. Parizel P.M., Degryse H.R., Gheuens J., et al. Gadolinium-DOTA enhanced MR imaging of intracranial lesions. J Comput Assist Tomogr 13 (1989) 378-385
15. Laissy J.P., Soyer P., Tebboune D., Tiah D., Hvass U., and Menu Y. Abdominal aortic aneurysms: assessment with gadolinium-enhanced time-of-flight coronal MR angiography (MRA). Eur J Radiol 20 (1995) 1-8
16. Lipski S., Baraton J., Mamou Mani T., Tavière V., Brunelle F., and Lallemand D. Utilization of gadolinium DOTA in the diagnosis of tumors of the central nervous system of the child. Diagn Interv Radiol 2 (1990) 163-167
17. Kaplan G.D., Aisen A.M., and Aravapalli S.R. Preliminary clinical trial of gadodiamide injection: a new nonionic gadolinium contrast agent for MR imaging. J Magn Reson Imaging 1 (1991) 57-62
18. Sze G., Brant-Zawadzki M., Haughton V.M., et al. Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine. Radiology 181 (1991) 693-699
19. Aslanian V., Lemaignen H., Bunouf P., Svaland M.G., Borseth A., and Lundby B. Evaluation of the clinical safety of gadodiamide injection, a new nonionic MRI contrast medium for the central nervous system: a European perspective. Neuroradiology 38 (1996) 537-541
20. Ekholm S.E., Jonsson E., Sandvik L., et al. Tolerance and efficacy of Omniscan (gadodiamide injection) in MR imaging of the central nervous system. Acta Radiol 37 (1996) 223-228
21. Ekholm S.E., Björk-Eriksson T., Western A., et al. MRI staging using gadodiamide for soft-tissue tumors of the head and neck region. Results from a phase II trial and a 5-year clinical follow-up. Eur J Radiol 39 (2001) 168-175
22. Martí-Bonmatí L., Vega T., Benito C., et al. Safety and efficacy of Omniscan (gadodiamide injection) at 0.1 mmol/kg for MRI in infants younger than 6 months of age: phase III open multicenter study. Invest Radiol 35 (2000) 141-147
23. Lundby B., Gordon P., and Hugo F. MRI in children given gadodiamide injection: safety and efficacy in CNS and body indications. Eur J Radiol 23 (1996) 190-196
24. Hanquinet S., Christophe C., Greef D.D., Gordon P., and Perlmutter N. Clinical evaluation of gadodiamide injection in paediatric MR imaging. Pediatr Radiol 26 (1996) 806-810
25. Runge V.M., Gelblum D.Y., Pacetti M.L., Carolan F., and Heard G. Gd-HP-DO3A in clinical MR imaging of the brain. Radiology 177 (1990) 393-400
26. Runge V.M., Dean B., Lee C., Carolan F., and Heard G. Phase III clinical evaluation of Gd-HP-DO3A in head and spine disease. J Magn Reson Imaging 1 (1991) 47-56
27. Runge V.M., Bradley W.G., Brant-Zawadzki M.N., et al. Clinical safety and efficacy of gadoteridol: a study in 411 patients with suspected intracranial and spinal disease. Radiology 181 (1991) 701-709
28. Zoarski G.H., Lufkin R.B., Bradley Jr. W.G., et al. Multicenter trial of gadoteridol, a nonionic gadolinium chelate, in patients with suspected head and neck pathology. AJNR Am J Neuroradiol 14 (1993) 955-961
29. Ball Jr. W.S., Nadel S.N., Zimmerman R.A., et al. Phase III multicenter clinical investigation to determine the safety and efficacy of gadoteridol in children suspected of having neurologic disease. Radiology 186 (1993) 769-774
30. Carvlin M.J., De Simone D.N., and Meeks M.J. Phase II clinical trial of gadoteridol injection, a low-osmolal magnetic resonance imaging contrast agent. Invest Radiol 27 Suppl. 1 (1992) S16-S21
31. McLachlan S.J., Francisco J.C., Pernicone J.R., and Hasso A.N. Efficacy evaluation of gadoteridol for MR angiography of intracranial vascular lesions. J Magn Reson Imaging 4 (1994) 405-411
32. Grossman R.I., Kuhn M.J., Maravilla K., et al. Multicenter evaluation of the safety, tolerance, and efficacy of OptiMARK in magnetic resonance imaging of the brain and spine. Acad Radiol 5 Suppl. 1 (1998) S154-S155; discussion S156
33. Lowe L.H., Kearns G.L., and Wible Jr. J.H. The safety and efficacy of neuroimaging with gadoversetamide injection in pediatric patients. Curr Med Res Opin 22 (2006) 2515-2524
34. Lemke A.J., Sander B., Balzer T., Geens V., Hosten N., and Felix R. Safety and use of gadobutrol in patients with brain tumors (phase III trial). RöFo 167 (1997) 591-598 [in German]
35. Benner T., Reimer P., Erb G., et al. Cerebral MR perfusion imaging: first clinical application of a 1 M gadolinium chelate (Gadovist 1.0) in a double-blinded randomized dose-finding study. J Magn Reson Imaging 12 (2000) 371-380
36. Tombach B., Benner T., Reimer P., et al. Do highly concentrated gadolinium chelates improve MR brain perfusion imaging? Intraindividually controlled randomized crossover concentration comparison study of 0.5 versus 1.0 mol/L gadobutrol. Radiology 226 (2003) 880-888
37. Schäfer F.K., Schäfer P.J., Jahnke T., et al. First clinical results in a study of contrast enhanced magnetic resonance angiography with the 1.0 molar gadobutrol in peripheral arterial occlusive disease-comparison to intra-arterial DSA. RöFo 175 (2003) 556-564 [in German]
38. Hentsch A., Aschauer M.A., Balzer J.O., et al. Gadobutrol-enhanced moving-table magnetic resonance angiography in patients with peripheral vascular disease: a prospective, multi-centre blinded comparison with digital subtraction angiography. Eur Radiol 13 (2003) 2103-2114
39. Herborn C.U., Goyen M., Quick H.H., et al. Whole-body 3D MR angiography of patients with peripheral arterial occlusive disease. AJR Am J Roentgenol 182 (2004) 1427-1434
40. Mohrs O.K., Oberholzer K., Krummenauer F., et al. Comparison of contrast-enhanced MR angiography of the aortoiliac vessels using a 1.0 molar contrast agent at 1.0 T with intra-arterial digital subtraction angiography. RöFo 176 (2004) 985-991 [in German]
41. Schäfer F.K., Schäfer P.J., Altjohann C., et al. A multicenter, site-independent, blinded study to compare the diagnostic accuracy of contrast-enhanced magnetic resonance angiography using 1.0 M gadobutrol (Gadovist) to intra-arterial digital subtraction angiography in body arteries. Eur J Radiol 61 (2007) 315-323
42. Schneider G., Kirchin M.A., Pirovano G., et al. Gadobenate dimeglumine-enhanced magnetic resonance imaging of intracranial metastases: effect of dose on lesion detection and delineation. J Magn Reson Imaging 14 (2001) 525-539
43. Balériaux D., Colosimo C., Ruscalleda J., et al. Magnetic resonance imaging of metastatic disease to the brain with gadobenate dimeglumine. Neuroradiology 44 (2002) 191-203
44. Cotton F. Diffusion-perfusion in intra-axial brain tumors with high relaxivity contrast agents. Neuroradiology 48 Suppl. 1 (2006) 34-40
45. Schneider G., Ballarati C., Grazioli L., et al. Gadobenate dimeglumine-enhanced MR angiography: diagnostic performance of four doses for detection and grading of carotid, renal, and aorto-iliac stenoses compared to digital subtraction angiography. J Magn Reson Imaging 26 (2007) 1020-1032
46. Kroencke T.J., Wasser M.N., Pattynama P.M., et al. Gadobenate dimeglumine-enhanced MR angiography of the abdominal aorta and renal arteries. AJR Am J Roentgenol 179 (2002) 1573-1582
47. Wikström J., Wasser M.N., Pattynama P.M., et al. Gadobenate dimeglumine-enhanced magnetic resonance angiography of the pelvic arteries. Invest Radiol 38 (2003) 504-515
48. Thurnher S., Miller S., Schneider G., et al. Diagnostic performance of gadobenate dimeglumine enhanced MR angiography of the iliofemoral and calf arteries: a large-scale multicenter trial. AJR Am J Roentgenol 189 (2007) 1223-1237
49. Anzalone N., Scomazzoni F., Castellano R., et al. Carotid artery stenosis: intraindividual correlations of 3D time-of-flight MR angiography, contrast-enhanced MR angiography, conventional DSA, and rotational angiography for detection and grading. Radiology 236 (2005) 204-213
50. Haustein J., Laniado M., Niendorf H.P., et al. Triple-dose versus standard-dose gadopentetate dimeglumine: a randomized study in 199 patients. Radiology 186 (1993) 855-860
51. Van Dijk P., Sijens P.E., Schmitz P.I., and Oudkerk M. Gd-enhanced MR imaging of brain metastases: contrast as a function of dose and lesion size. Magn Reson Imaging 15 (1997) 535-541
52. Sze G., Johnson C., Kawamura Y., et al. Comparison of single- and triple-dose contrast material in the MR screening of brain metastases. AJNR Am J Neuroradiol 19 (1998) 821-828
53. Heverhagen J.T., Reitz I., Pavlicova M., Levine A.L., Klose K.J., and Wagner H.J. The impact of the dosage of intravenous gadolinium-chelates on the vascular signal intensity in MR angiography. Eur Radiol 17 (2007) 626-637
54. Jourdan C., Heverhagen J.T., and Knopp M.V. Dose comparison of single- vs. double-dose in contrast-enhanced magnetic resonance angiography of the carotid arteries: intraindividual cross-over blinded trial using Gd-DTPA. J Magn Reson Imaging 25 (2007) 557-563
55. Demaerel P., Marchal G., Wilms G., et al. Gadodiamide injection at 0.1 and 0.3 mmol/kg body weight: a phase III double-blind, parallel, randomised clinical investigation of known or suspected central nervous system lesions at 1.5 T. Neuroradiology 36 (1994) 355-359
56. Krause U., Kroencke T., Spielhaupter E., et al. Contrast-enhanced magnetic resonance angiography of the lower extremities: standard-dose vs. high-dose gadodiamide injection. J Magn Reson Imaging 21 (2005) 449-454
57. Runge V.M., Kirsch J.E., Burke V.J., Price A.C., Nelson K.L., Thomas G.S., et al. High-dose gadoteridol in MR imaging of intracranial neoplasms. J Magn Reson Imaging 2 (1992) 9-18
58. Yuh W.T., Engelken J.D., Muhonen M.G., Mayr N.A., Fisher D.J., and Ehrhardt J.C. Experience with high-dose gadolinium MR imaging in the evaluation of brain metastases. AJNR Am J Neuroradiol 13 (1992) 335-345
59. Yuh W.T., Fisher D.J., Runge V.M., et al. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases. AJNR Am J Neuroradiol 15 (1994) 1037-1051
60. Yuh W.T., Tali E.T., Nguyen H.D., Simonson T.M., Mayr N.A., and Fisher D.J. The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis. AJNR Am J Neuroradiol 16 (1995) 373-380
61. Yuh W.T., Tali E.T., Nguyen H.D., Simonson T.M., Mayr N.A., and Fisher D.J. Erratum in. AJNR Am J Neuroradiol 16 (1995) 1384
62. Mayr N.A., Yuh W.T., Muhonen M.G., et al. Cost-effectiveness of high-dose MR contrast studies in the evaluation of brain metastases. AJNR Am J Neuroradiol 15 (1994) 1053-1061
63. Vogl T.J., Friebe C.E., Balzer T., et al. Diagnosis of cerebral metastasis with standard dose gadobutrol vs. a high dose protocol. Intraindividual evaluation of a phase II high dose study. Radiologe 35 (1995) 508-516 [in German]
64. Knauth M., Forsting M., Hartmann M., Heiland S., Balzer T., and Sartor K. MR enhancement of brain lesions: increased contrast dose compared with magnetization transfer. AJNR Am J Neuroradiol 17 (1996) 1853-1859
65. Brugières P., Gaston A., Degryse H.R., et al. Randomised double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA). Neuroradiology 36 (1994) 27-30
66. Oudkerk M., Sijens P.E., Van Beek E.J., and Kuijpers T.J. Safety and efficacy of Dotarem (Gd-DOTA) versus Magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Invest Radiol 30 (1995) 75-78
67. Myhr G., Rinck P.A., and Børseth A. Gadodiamide injection and gadopentetate dimeglumine. A double-blind study in MR imaging of the CNS. Acta Radiol 33 (1992) 405-409
68. Balériaux D., Matos C., and De Greef D. Gadodiamide injection as a contrast medium for MRI of the central nervous system: a comparison with gadolinium-DOTA. Neuroradiology 35 (1993) 490-494
69. Valk J., Algra P.R., Hazenberg C.J., Slooff W.B., and Svaland M.G. A double-blind, comparative study of gadodiamide injection and gadopentetate dimeglumine in MRI of the central nervous system. Neuroradiology 35 (1993) 173-177
70. Akeson P., Jonsson E., Haugen I., and Holtås S. Contrast-enhanced MRI of the central nervous system: comparison between gadodiamide injection and gadolinium-DTPA. Neuroradiology 37 (1995) 229-233
71. Schäfer P.J., Boudghene F.P., Brambs H.J., et al. Abdominal and iliac arterial stenoses: comparative double-blinded randomized study of diagnostic accuracy of 3D MR angiography with gadodiamide or gadopentetate dimeglumine. Radiology 238 (2006) 827-840
72. Greco A., Parker J.R., Ratcliffe C.G., Kirchin M.A., and McNamara M.T. Phase III, randomized, double-blind, cross-over comparison of gadoteridol and gadopentetate dimeglumine in magnetic resonance imaging of patients with intracranial lesions. Australas Radiol 45 (2001) 457-463
73. Rubin D.L., Desser T.S., Semelka R., et al. A multicenter, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: results of a Phase III clinical trial. J Magn Reson Imaging 9 (1999) 240-250
74. Grossman R.I., Rubin D.L., Hunter G., et al. Magnetic resonance imaging in patients with central nervous system pathology: a comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (Gd-DTPA). Invest Radiol 35 (2000) 412-419
75. Fink C., Puderbach M., Ley S., et al. Contrast-enhanced three-dimensional pulmonary perfusion magnetic resonance imaging: intraindividual comparison of 1.0 M gadobutrol and 0.5 M Gd-DTPA at three dose levels. Invest Radiol 39 (2004) 143-148
76. Goyen M., Lauenstein T.C., Herborn C.U., Debatin J.F., Bosk S., and Ruehm S.G. 0.5 M Gd chelate (Magnevist) versus 1.0 M Gd chelate (Gadovist): dose-independent effect on image quality of pelvic three-dimensional MR-angiography. J Magn Reson Imaging 14 (2001) 602-607
77. Goyen M., Herborn C.U., Vogt F.M., et al. Using a 1 M Gd-chelate (gadobutrol) for total-body three-dimensional MR angiography: preliminary experience. J Magn Reson Imaging 17 (2003) 565-571
78. Colosimo C., Ruscalleda J., Korves M., et al. Detection of intracranial metastases: a multicenter, intrapatient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dosage. Invest Radiol 36 (2001) 72-81
79. Essig M., Hartmann M., Lodemann K.P., et al. Comparison of contrast behavior of gadobenate-dimeglumine and Gd-DTPA in intra-axial brain tumors. A double-blind randomized intraindividual cross-over study. Radiologe 41 (2001) 1063-1071 [in German]
80. Colosimo C., Knopp M.V., Barreau X., et al. A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours. Neuroradiology 46 (2004) 655-665
81. Knopp M.V., Runge V.M., Essig M., et al. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology 230 (2004) 55-64
82. Essig M., Tartaro A., Tartaglione T., Pirovano G., Kirchin M.A., and Spinazzi A. Enhancing lesions of the brain: intraindividual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators. Acad Radiol 13 (2006) 744-751
83. Maravilla K.R., Maldjian J.A., Schmalfuss I.M., et al. Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology 240 (2006) 389-400
84. Kuhn M.J., Picozzi P., Maldjian J.A., et al. Evaluation of intra-axial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. J Neurosurg 106 (2007) 557-566
85. Runge V.M., Armstrong M.R., Barr R.G., et al. A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology. Invest Radiol 36 (2001) 65-71
86. Runge V.M., Parker J.R., and Donovan M. Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain. Invest Radiol 37 (2002) 269-280
87. von Tengg-Kobligk H., Floemer F., and Knopp M.V. Multiphasic MR angiography as an intra-individual comparison between the contrast agents Gd-DTPA, Gd-BOPTA, and Gd-BT-DO3A. Radiologe 43 (2003) 171-178 [in German]
88. Knopp M.V., Giesel F.L., von Tengg-Kobligk H., et al. Contrast-enhanced MR angiography of the run-off vasculature: intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine. J Magn Reson Imaging 17 (2003) 694-702
89. Wyttenbach R., Gianella S., Alerci M., Braghetti A., Cozzi L., and Gallino A. Prospective blinded evaluation of Gd-DOTA- versus Gd-BOPTA-enhanced peripheral MR angiography, as compared with digital subtraction angiography. Radiology 227 (2003) 261-269
90. Prokop M., Schneider G., Vanzulli A., et al. Contrast-enhanced MR Angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology 234 (2005) 399-408
91. Essig M., Lodemann K.P., LeHuu M., Schönberg S.O., Hübener M., and Van Kaick G. Comparison of MultiHance and Gadovist for cerebral MR perfusion imaging in healthy volunteers [in German]. Radiologe 42 (2002) 909-915
92. Thilmann O., Larsson E.M., Björkman-Burtscher I.M., Ståhlberg F., and Wirestam R. Comparison of contrast agents with high molarity and with weak protein binding in cerebral perfusion imaging at 3 T. J Magn Reson Imaging 22 (2005) 597-604
93. Essig M., Lodemann K.P., Le-Huu M., Brüning R., Kirchin M., and Reith W. Intraindividual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5 T. Invest Radiol 41 (2006) 256-263
94. Herborn C.U., Lauenstein T.C., Ruehm S.G., Bosk S., Debatin J.F., and Goyen M. Intra-individual comparison of gadopentetate dimeglumine, gadobenate dimeglumine, and gadobutrol for pelvic 3D magnetic resonance angiography. Invest Radiol 38 (2003) 27-33